All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-06-23T13:02:27.000Z

What insights can multi-omics provide into the mechanism of disease progression in WM?

Jun 23, 2023
Share:

Bookmark this article

On behalf of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), the Lymphoma Hub was pleased to speak with Zachary Hunter, Dana-Farber Cancer Institute, Boston, US. We asked, What insights can multi-omics provide into the mechanism of disease progression in Waldenstrom’s macroglobulinemia (WM)?

What insights can multi-omics provide into the mechanism of disease progression in WM?

Hunter begins by highlighting the importance of multi-omics in understanding the disease biology of WM, which allows better diagnosis and guides in developing targeted treatment strategies. He then goes on to discuss how focusing on DNA and RNA as “tools” is used for local regulation of genes, as well as how general epigenomics can be used to create targeted therapeutics. In addition, Hunter emphasizes the importance of using a treatment that specifically targets cancerous cells without harming healthy cells. Finally, he touches on how understanding the disease molecular mechanism is vital in multi-omics to create clusters of characteristics to better understand an individual’s disease progression and a patient’s treatment response.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox